Citations

Clear

6274 citation(s) found for "To, Andrew".

Solanezumab in‐depth outcomes
Farlow, Martin R. , Clifford, David B. , Coalier, Kelley A., Fagan, Anne M. , Gordon, Brian A., Mills, Susan , Morris, John C., Salloway, Stephen P., Santacruz, Anna , Wang, Guoqiao , Snider, B. Joy, Mummery, Catherine J. , Surti, Ghulam M., Hannequin, Didier , Jiménez‐Velázquez, Ivonne Z. , Dyck, Christopher H. van , Gauthier, Serge , Galasko, Doug, Jayadev, Suman , Formaglio, Maïté, Clarnette, Roger, Pariente, Jérémie , Dubois, Bruno, Andersen, Scott W. , Holdridge, Karen C. , Mintun, Mark A., Sims, John R. , Yaari, Roy, Team, DIAN‐TU Study, Bateman, Randall J. , Aschenbrenner, Andrew J. , Benzinger, Tammie L.S. , Cruchaga, Carlos , Goate, Alison , Gordon, Brian A. , Hassenstab, Jason , Jack, Clifford R. , Koeppe, Robert A. , McDade, Eric , Morris, John C. , Snyder, Peter J. , Xiong, Chengjie , Wallon, David , Berman, Sarah , Lah, James J. , Roberson, Erik D. , Honig, Lawrence S. , Sánchez‐Valle, Raquel , Brooks, William S. , Masters, Colin L. , Brosch, Jared R. , Hsiung, Ging‐Yuek Robin , Masellis, Mario , Dubois, Bruno, Pasquier, Florence , Yaari, R. , Team, DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S9 | Pages: No page available

10.1002/alz.038028 Get It

AbstractBackgroundSolanezumab is a monoclonal antibody targeting soluble forms of β‐amyloid protein important in the pathogenesis of Alzheimer’s disease (AD). Three previous 18‐month double‐blind placebo‐controlled trials of low‐dose solanezumab in late‐onset sporadic AD found inconsistent benefits on cognitive and functional assessments. Dominantly‐inherited mutation‐associated AD subjects both before and after onset of symptoms form an ideal population to study potential benefits of solanezumab therapy.MethodMutation‐carrying asymptomatic (CDR 0, N=41) or mildly symptomatic (CDR 0.5 – 1, N=28) patients were treated for a minimum of 4 years and up to 7 years in a double‐blind 3 to 1 active versus placebo randomized clinical trial that measured disease progression by clinical, neuropsychological and biomarker evaluations. The trial was initiated with a dose of 400 mg every 4 weeks and escalated to 1600 mg when low dose trials in sporadic AD did not meet their primary endpoints. The primary cognitive outcome measure was DIAN‐MCE, composed of Delayed Recall Score of the International Shopping List Test, the Delayed Recall score of the Logical Memory IIa subtest from the Wechsler Memory Scale‐Revised, the Digit Symbol Substitution Test total score from the WAIS‐R and the MMSE total score. Secondary outcomes included a battery of other cognitive and functional measures. The study was powered to detect delay of cognitive disease progression in the DIAN‐MCE. Biomarkers include imaging modalities (volumetric MRI, FDG, amyloid and Tau PET). CSF markers included β‐amyloid, Tau and PhosphoTau species. NfL was measured in both CSF and plasma. The study used a pre‐specified Bayesian multivariate disease progression model, which included dynamic borrowing of control subjects from the DIAN Observational study.ResultThe topline efficacy, safety and biomarker results will be reported.ConclusionThis study provides the first test of targeting soluble abeta forms in DIAD. It addresses the efficacy of early initiation of higher doses of solanezumab targeting soluble forms of amyloid as a disease modifying therapy. While these results are specific to DIAD, they have the potential to inform the application of anti‐amyloid therapy in sporadic AD.
The Military Orthopedics Tracking Injuries and Outcomes Network: A Solution for Improving Musculoskeletal Care in the Military Health System
Mauntel, Timothy C. , Freedman, Brett A. , Provencher, Matthew T. , Tokish, John M. , Lee, Ian E, Bailey, James R. , Burns, Travis C. , Cameron, Kenneth L. , Grenier, Eric, Haley, Chad A., McDonald, Lucas S. , Pallis, Mark, Posner, Matthew, Rivera, Jessica C. , Roach, Christopher J, Robins, Richard J. , Sheean, Andrew J. , Slabaugh, Mark A. , Volk, William R., Dickens, Jonathan F. , Dickens, Jonathan F , Tenan, Matthew S. , Potter, Benjamin Kyle , Provencher, Matthew T. , Rhon, Daniel I. , LeClere, Lance E. , Owens, Brett D. , Roach, Christopher J, Schmitz, Matthew R.

Mayo Clinic

Military Medicine | December 6, 2020 | Volume: 187 | Issue: 3-4 | Pages: e282-e289

10.1093/milmed/usaa304 | PMID 33242087 Get It

Abstract Introduction Musculoskeletal injuries are an endemic amongst U.S. Military Service Members and significantly strain the Department of Defense’s Military Health System. The Military Health System aims to provide Service Members, military retirees, and their families the right care at the right time. The Military Orthopedics Tracking Injuries and Outcomes Network (MOTION) captures the data that can optimize musculoskeletal care within the Military Health System. This report provides MOTION structural framework and highlights how it can be used to optimize musculoskeletal care. Materials and Methods MOTION established an internet-based data capture system, the MOTION Musculoskeletal Data Portal. All adult Military Health System patients who undergo orthopedic surgery are eligible for entry into the database. All data are collected as routine standard of care, with patients and orthopedic surgeons inputting validated global and condition-specific patient reported outcomes and operative case data, respectively. Patients have the option to consent to allow their standard of care data to be utilized within an institutional review board approved observational research study. MOTION data can be merged with other existing data systems (e.g., electronic medical record) to develop a comprehensive dataset of relevant information. In pursuit of enhancing musculoskeletal injury patient outcomes MOTION aims to: (1) identify factors which predict favorable outcomes; (2) develop models which inform the surgeon and military commanders if patients are behind, on, or ahead of schedule for their targeted return-to-duty/activity; and (3) develop predictive models to better inform patients and surgeons of the likelihood of a positive outcome for various treatment options to enhance patient counseling and expectation management. Results This is a protocol article describing the intent and methodology for MOTION; thus, to date, there are no results to report. Conclusions MOTION was established to capture the data that are necessary to improve military medical readiness and optimize medical resource utilization through the systematic evaluation of short- and long-term musculoskeletal injury patient outcomes. The systematic enhancement of musculoskeletal injury care through data analyses aligns with the National Defense Authorization Act (2017) and Defense Health Agency’s Quadruple Aim, which emphasizes optimizing healthcare delivery and Service Member medical readiness. This transformative approach to musculoskeletal care can be applied across disciplines within the Military Health System.
NCOG-15. PREGNANCY AND GLIOMA
Rodriguez, Andrew , Ruff, Michael W.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii132-ii132

10.1093/neuonc/noaa215.554 Get It

Abstract Improvements in treatments and prognosis in glioma patients has led patients the opportunity for pregnancy despite their diagnosis. In this retrospective case series of 13 patients evaluated at Mayo Clinic, we identified patients who were pregnant at or after glioma diagnosis from 1998-2019. Clinical information was obtained through the electronic medical record. Tumor grade, treatments, peripartum complications, and pediatric outcomes were analyzed. Median follow-up for pregnant patients was 13.5 years (range, 0-24). Of the 13 patients, 2 patients received temozolomide and radiation during pregnancy for glioblastoma and had no peripartum complications. Median survival time in these patients after further treatments was 23.5 months (range, 23.3-23.8). Two children from these pregnancies had no fetal malformations or pediatric developmental delays with median follow-up of 8.8 years (range, 4.7-12.8). Three patients received radiation during pregnancy for high grade gliomas and had no fetal malformations or peripartum complications. Eight patients had one or multiple pregnancies with median 2 (range, 1-3) children at or after diagnosis with 14 children total. Eleven of the 14 children had no fetal malformations or peripartum complications and were conceived without reproductive assistive technologies. Two children, who were identical twins, were born with a placental malformation but otherwise had normal pediatric development. One child was born pre-term and had long-term developmental delays.
HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
Chi, Andrew , Kurz, Sylvia C. , Wen, Patrick Y. , Arrillaga‐Romany, Isabel , Batchelor, Tracy T. , Butowski, Nicholas , Shonka, Nicole , DeGroot, John, Hall, Matthew D. , Daghistani, Doured , Schwartz, Jonathan , Cartaxo, Rodrigo T. , Siada, Ruby , Miklja, Zachary , Bruzek, Amy K., Wierzbicki, Kyle , Paul, Alyssa , Wolfe, Ian, Leaoard, Marcia, Garton, Hugh , Mody, Rajen , Robertson, Patricia L. , Merdinger, Krystal, Venneti, Sriram , Oster, Wolfgang, Allen, Joshua E. , Kawakibi, Abed Rahman , Tarapore, Rohinton S. , Gardner, Sharon L , Wen, Patrick Yung , Arrillaga‐Romany, Isabel , Sumrall, Ashley , Harrison, Rebecca A , Mehta, Minesh P. , Odia, Yazmín , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Umemura, Yoshie , Yadav, Viveka Nand , Cantor, Evan , Lu, Guangrong , Koschmann, Carl

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_3 | Pages: iii347-iii347

10.1093/neuonc/noaa222.305 Get It

Abstract ONC201, a bitopic DRD2 antagonist and allosteric ClpP agonist, has shown encouraging efficacy in H3 K27M-mutant glioma. Given that the thalamus has the highest extra-striatal expression of DRD2, we performed an integrated preclinical and clinical analysis of ONC201 in thalamic H3 K27M-mutant glioma. ONC201 was effective in mouse intra-uterine electroporation (IUE)-generated H3 K27M-mutant gliomas, with an in vitro IC50 of 500 nM and 50% prolongation of median survival in vivo (p=0.02, n=14). We analyzed thalamic H3 K27M-mutant glioma patients treated with ONC201 on active clinical trials as of 5/22/19 enrollment (n=19 recurrent and 10 post-radiation, non-recurrent; 5–70 years old). As of 12/18/2019, PFS6 and OS12 are 26.3% and 36.8%, respectively, in the recurrent group. For non-recurrent patients, with median follow up of 21.9 months (8.6–26.6) from diagnosis, median PFS or OS have not been reached. This surpasses historical OS of 13.5 months. Best response by RANO includes 1 CR, 3 PR, 4 SD, 8 PD for recurrent patients and 2 PR, 4 SD, 1 PD for non-recurrent patients (4 on-trial patients experienced regressions that are yet unconfirmed responses). Median duration of response for recurrent patients is 14.0 months (2.0–33.1). Furthermore, H3 K27M cell-free tumor DNA in plasma and CSF correlated with MRI response. In summary, single agent ONC201 administered at recurrence, or adjuvantly following radiation, demonstrates promising clinical efficacy in thalamic H3 K27M-mutant glioma patients who currently have no effective treatments following radiation. Investigations are ongoing to assess whether micro-environmental DRD2 expression explains the early exceptional responses in thalamic H3 K27M-mutant glioma.
CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL
Rahman, Rifaquat , Trippa, Lorenzo , Fell, Geoffrey, Lee, Eudocia Q. , Arrillaga‐Romany, Isabel , McCluskey, Christine , Brunno, Jennifer, Gaffey, Sarah, Lassman, Andrew B. , Ahluwalia, Manmeet S. , Colman, Howard , Hepel, Jaroslaw T., Elinzano, Heinrich, Schiff, David , Chukwueke, Ugonma , Nayak, Lakshmi , Batchelor, Tracy T. , Rinne, Mikael L. , Lu‐Emerson, Christine , Haas‐Kogan, Daphne A. , Cagney, Daniel , Aizer, Ayal A. , Welch, Mary , Doherty, Lisa, Lavallee, Maria, Fisher-Longden, Brittany, Dowling, Shanna, Watkinson, Fiona , Reardon, David A. , Wen, Patrick Y. , Ahluwalia, Manmeet S , Fell, Geoffrey G. , Arrillaga‐Romany, Isabel , Touat, Mehdi , Drappatz, Jan , Galanis, Evanthia , Colman, Howard , Nabors, Burt , Beroukhim, Rameen , McFaline-Figueroa, J Ricardo , Kaley, Thomas , Bi, Wenya Linda , Arnaout, Omar M. , Tanguturi, Shyam K , Geduldig, Jack , Santagata, Sandro , Meredith, David M. , Chiocca, E Antonio , Ligon, Keith L , Alexander, Brian M. , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii43-ii44

10.1093/neuonc/noaa215.178 Get It

Abstract BACKGROUND CC-115 is an oral, CNS-penetrant, selective inhibitor of mammalian target of rapamycin kinase (mTOR) and deoxyribonucleic acid-dependent protein kinase (DNA-PK). Both targets are important in glioblastoma; PI3K/Akt/mTOR signaling is hyperactive in most glioblastomas, and DNA-PK is integral to repair of radiotherapy-mediated DNA damage. To investigate CC-115 in newly diagnosed glioblastoma and explore potential genomic biomarker associations, CC-115 was evaluated in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial, an adaptive platform trial designed to efficiently test experimental agents. METHODS Adults with newly diagnosed MGMT-unmethylated glioblastoma, with genomic data available, are eligible for this ongoing trial. Patients are adaptively randomized to one of several experimental arms or the control arm: standard radiotherapy with concurrent and adjuvant temozolomide. The primary endpoint is overall survival (OS). Patients randomized to CC-115 (10mg po BID) received it concurrently with radiotherapy and as adjuvant monotherapy. As the first in-human use of CC-115 with radiation, a safety lead-in 3 + 3 design was used. RESULTS Twelve patients were randomized to CC-115; seven patients had possible treatment-related CTCAE grade > 3 toxicity, including four pre-specified dose-limiting toxicities: liver function abnormality (n=1), hyperlipidemia (n=1), lipase elevation (n=1) and cerebral edema (n=1). There was no significant difference in progression-free survival (PFS, median 4.2 months [CC-115] vs. 5.2 months, p=0.9) or OS (median 10.1 months [CC-115] vs. 14.5 months, p=0.9) compared to the 50 patients randomized to the control arm. Based on early PFS results, randomization probability to CC-115 decreased from 25% to < 10% at time of the trial arm closure. CONCLUSION Concurrent and adjuvant CC-115 was associated with toxicity and failed to improve PFS or OS. The INSIGhT trial design allowed for more efficient testing of CC-115, decreasing patients and resources allocated to a therapy that was discontinued due to concerns about toxicity and unfavorable risk-to-benefit ratio.
CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION
Wen, Patrick Y. , Trippa, Lorenzo , Lee, Eudocia Q. , Fell, Geoffrey, Rahman, Rifaquat , Arrillaga‐Romany, Isabel , McCluskey, Christine , Brunno, Jennifer, Gaffey, Sarah, Lassman, Andrew B. , Ahluwalia, Manmeet S. , Colman, Howard , Hepel, Jaroslaw T., Elinzano, Heinrich, Schiff, David , Chukwueke, Ugonma , Nayak, Lakshmi , Batchelor, Tracy T. , Rinne, Mikael L. , Lu‐Emerson, Christine , Doherty, Lisa, Haas‐Kogan, Daphne A. , Cagney, Daniel , Aizer, Ayal A. , Welch, Mary , Lavallee, Maria, Fisher-Longden, Brittany, Dowling, Shanna, Reardon, David A. , Ahluwalia, Manmeet S , Wen, Patrick Yung , Fell, Geoffrey G. , Arrillaga‐Romany, Isabel , Touat, Mehdi , Drappatz, Jan , Galanis, Evanthia , Colman, Howard , Nabors, Burt , Beroukhim, Rameen , McFaline-Figueroa, J Ricardo , Kaley, Thomas , Bi, Wenya Linda , Arnaout, Omar M. , Peruzzi, Pier Paolo , Tanguturi, Shyam K , Geduldig, Jack , Santagata, Sandro , Meredith, David M. , Chiocca, E Antonio , Ligon, Keith L , Alexander, Brian M.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii44-ii44

10.1093/neuonc/noaa215.179 Get It

Abstract BACKGROUND The cyclin D-CDK4/6-Rb pathway is activated in most glioblastomas. Abemaciclib is a potent CDK4/6 inhibitor with good brain penetration approved for ER/PR/HER2- breast cancer. In order to efficiently evaluate the potential impact of abemaciclib on overall survival (OS) in newly diagnosed glioblastoma and to simultaneously develop information regarding potential genomic biomarker associations, abemaciclib was included as an arm on the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial. INSIGhT is a phase II platform trial using response adaptive randomization and deep genomic profiling to more efficiently test experimental agents in MGMT unmethylated glioblastoma and potentially accelerate identification of novel therapies for phase III testing. Initial randomization was equal between abemaciclib, control, and two other experimental arms but subsequent randomization was adapted based on efficacy as determined by progression-free survival (PFS). Ineffective arms were discontinued and new arms added by protocol amendment. We report preliminary results for the abemaciclib arm which has completed accrual. METHODS Patients with newly diagnosed MGMT-unmethylated glioblastoma were randomized to receive either radiotherapy with concomitant and adjuvant temozolomide at standard doses or standard radiochemotherapy followed by adjuvant abemaciclib (150–200 mg orally BID) without temozolomide. Treatment continued until progression or development of unacceptable toxicities. The primary endpoint was OS. Association between abemaciclib efficacy and cyclin D-CDK4/6-Rb pathway genomic alterations was also investigated. RESULTS There were 123 patients (50 control; 73 treated with abemaciclib). Abemaciclib was generally well-tolerated with no new toxicity signals identified. PFS was significantly longer (p=0.03, logrank test) with abemaciclib (median 6.31 months 95% CI [5.29, 8.18]) compared to the control arm (5.16 months 95% CI [4.37, 6.28]). 28/50 control and 36/73 abemaciclib patients remain alive. CONCLUSION Preliminary analysis suggests that abemaciclib increases PFS compared to control. Updated toxicity, PFS and survival data and potential genomic biomarker associations will be presented.
Testing the Feasibility and Acceptability of a Religiously-Tailored Text Messaging Intervention to Reduce Smoking Among Somali Muslim Men During Ramadan
Pratt, Rebekah , Ojo-Fati, Olamide, DuBois, Diana K., Okuyemi, Kolawole S. , Graham, Amanda L. , Mohamed, Sharif, Janowiec, Mark , Kahin, Abdillahi, Mahamud, Abdirahman , Tessier, Katelyn , Busch, Andrew M. , Graham, Amanda L , Joseph, Anne M.

Mayo Clinic

Nicotine & Tobacco Research | December 3, 2020 | Volume: 23 | Issue: 8 | Pages: 1283-1290

10.1093/ntr/ntaa260 | PMID 33277991 Get It

Abstract Introduction The prevalence of smoking among Somali Muslim male immigrants residing in Minnesota is estimated at 44%, however smoking reduction is common during the month of Ramadan. This study evaluated the feasibility and impact of a religiously tailored text message intervention delivered during Ramadan to encourage smoking reduction among Somali Muslim men who smoke. Methods Fifty Somali men were recruited. Participants received two text messages per day starting 1 week prior to and throughout the month of Ramadan. Approximately half were religiously tailored and half were about the risks of smoking and benefits of quitting. Smoking behavior was assessed at baseline, and at weeks 4 (end of Ramadan), 8, and 16. Outcomes included feasibility, acceptability, and preliminary impact of the text message intervention on smoking reduction and bioverified abstinence. Results The average age was 41 years. Average time to first cigarette was 1.8 hours at baseline, and 46% of participants smoked menthol cigarettes. Eighteen of 50 participants selected English and 32 selected Somali text messages. Subjects significantly reduced self-reported cigarettes per day (CPD) from 12.4 CPD at baseline to 5.8 CPD at week 16 (p < 0.001). Seven subjects reported quitting at week 16, five completed CO testing, confirming self-reported abstinence. The majority of participants found the cultural and religious references encouraging at the end of the week 16 survey. Conclusions Religiously tailored text messages to decrease smoking are feasible and acceptable to Somali Muslim men who smoke during Ramadan. This intervention for addressing smoking disparities is worthy of further study. Implications Recruitment of Somali Muslim men who smoke is feasible and supports the idea that further studies targeting smoking during Ramadan are practical. Ramadan presents a window of opportunity upon which to build smoking cessation interventions for smokers who identify as Muslim. These preliminary findings suggest that text messaging is a feasible and acceptable intervention strategy, and that religious tailoring was well received. Such an approach may offer potential for addressing smoking disparities among Somali Muslim male smokers. Trial Registration ClinicalTrial.gov: NCT03379142
Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies
Jabbour, Salma K. , Williams, Terence M. , Sayan, Mutlay , Ajani, Jaffer A. , Chang, Andrew C. , Coleman, Norman, El‐Rifai, Wael , Haddock, Michael G. , Ilson, David H. , Jamorabo, Daniel S. , Kunos, Charles A., Liu, Geoffrey , Prasanna, Pataje G.S. , Rustgi, Anil K. , Wong, Rosemary , Vikram, Bhadrasain , Ahmed, Mansoor M. , Ajani, Jaffer A , Chang, Andrew C , Haddock, Michael, Jamorabo, Daniel , Ahmed, Mansoor M , Liu, Geoffrey , Williams, Terence M , Jabbour, Salma K , Miller, Eric D. , Lin, Steven H.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 1, 2020 | Volume: 113 | Issue: 6 | Pages: 665-679

10.1093/jnci/djaa195 | PMID 33351071 Get It

AbstractAlthough the development of effective combined chemoradiation regimens for esophageal cancers has resulted in statistically significant survival benefits, the majority of patients treated with curative intent develop locoregional and/or distant relapse. Further improvements in disease control and survival will require the development of individualized therapy based on the knowledge of host and tumor genomics and potentially harnessing the host immune system. Although there are a number of gene targets that are amplified and proteins that are overexpressed in esophageal cancers, attempts to target several of these have not proven successful in unselected patients. Herein, we review our current state of knowledge regarding the molecular pathways implicated in esophageal carcinoma, and the available agents for targeting these pathways that may rationally be combined with standard chemoradiation, with the hope that this commentary will guide future efforts of novel combinations of therapy.
Endoscopic Ultrasound-Guided Gastrojejunostomy and Rescue Technique to Simplify Endoscopic Retrograde Cholangiopancreatography in Surgically Altered Anatomy
Chin, Jerry Yung‐Lun , Chin, Jerry, Chin, Jerry, Storm, Andrew C.

Mayo Clinic

ACG Case Reports Journal | December 1, 2020 | Volume: 7 | Issue: 11 | Pages: e00482

10.14309/crj.0000000000000482 | PMID 33269291 Get It

ABSTRACT Patients with surgically altered gastrointestinal anatomy are susceptible to gallstone disease and anastomotic strictures. In such cases, enteroscopy-assisted endoscopic retrograde cholangiopancreatography (ERCP) is traditionally used to access the biliary system through the Roux limb, with suboptimal success rates. With the advent of endoscopic ultrasound (EUS) and therapeutic tools including lumen-apposing metal stents, access to the biliary system in surgically altered anatomy has been made simpler. We report a case of EUS-guided transenteric ERCP done in a patient with surgically altered anatomy and a rescue technique for difficult gastrojejunal anastomosis creation.
Effects of daily 24-gram doses of rice or whey protein on resistance training adaptations in trained males
Moon, Jessica M. , Ratliff, Kayla M., Blumkaitis, Julia C., Zabriskie, Hannah A. , Stecker, Richard A., Jäger, Ralf , Purpura, Martin , Harty, Patrick S , Zabriskie, Hannah A , Jagim, Andrew R , Jäger, Ralf , Kerksick, Chad M , Harty, Patrick S. , Currier, Brad S. , Jagim, Andrew R. , Kerksick, Chad M.

Mayo Clinic

Journal of the International Society of Sports Nutrition | December 1, 2020 | Volume: 17 | Issue: 1 | Pages: No page available

10.1186/s12970-020-00394-1 | PMID 33261645 Get It